Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07224854 · ClinicalTrials.gov registry record

Epigenetic Signature for CRC Early Detection

A clinical trial of Early Detection of Cancer and Cell-free DNA, sponsored by City of Hope Medical Center.

Active
Registry status
500
Enrollment target
1
Study location

NCT07224854: Active study of Early Detection of Cancer and Cell-free DNA, sponsored by City of Hope Medical Center.

NCT07224854 is a study of Early Detection of Cancer and Cell-free DNA that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 500 participants, below the 37,703-participant average among 8 other Early Detection of Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07224854, a study of Early Detection of Cancer and Cell-free DNA, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

The epiCED is a noninvasive blood-based assay designed for early detection of colorectal cancer (CRC) using circulating cell-free DNA (cfDNA) 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) epigenetic markers. This study leverages retrospective, multi-center cohorts of CRC patients and non-cancer controls to discover and validate a robust cfDNA methylation signature. Small-scale sequencing and machine learning-based modeling will be applied to identify a minimal panel of methylation markers that can accurately discriminate CRC from non-cancer individuals, including early-stage disease. The ultimate goal is to develop a clinically practical, noninvasive screening tool that enables population-level early detection and improves patient outcomes.

Primary Outcome

Proportion of true positive CRC cases correctly identified by the cfDNA methylation panel.

Conditions Studied

Early Detection of Cancer Cell-free DNA Colorectal Cancer (Diagnosis) Non-cancer Controls DNA Methylation

Study Locations (1)

California

  • City of Hope Nat Medical Ctr - Monrovia

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2024-06-21
Est. Completion 2026-06-18
City of Hope Medical Center

582 total trials

What the registry record for NCT07224854 still lists

NCT07224854 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 37,703-participant average among 8 other Early Detection of Cancer trials with a reported enrollment target (99% lower).

The record links to 5 conditions, with Early Detection of Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT07224854 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT07224854 about?

NCT07224854 is a clinical study titled "Epigenetic Signature for CRC Early Detection". The epiCED is a noninvasive blood-based assay designed for early detection of colorectal cancer (CRC) using circulating cell-free DNA (cfDNA) 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) epigenetic markers. This study leverages retrospective, multi-center cohorts of CRC patients and non...

What is the current status of trial NCT07224854?

This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2024-06-21. Estimated completion is 2026-06-18.

What conditions does trial NCT07224854 study?

This clinical trial studies the following conditions: Early Detection of Cancer, Cell-free DNA, Colorectal Cancer (Diagnosis), Non-cancer Controls, DNA Methylation.

Who is sponsoring clinical trial NCT07224854?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07224854 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Early Detection of Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07224854's enrollment target sits among peer trials

500 7th of 8 higher than 2 of 8 other Early Detection of Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Early Detection of Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT07224854, the US trial registry maintained by the National Library of Medicine. NCT07224854 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.